Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

With FDA approval of the six-minute walk test as primary endpoint, private specialty firm hopes to bring first Duchenne muscular dystrophy drug to market within two years.
Advertisement

Related Content

A Pair Of GEMS: PTC Unveils Two Platform-Based Deals In One Day
A Pair Of GEMS: PTC Unveils Two Platform-Based Deals In One Day
R&D, In Brief
R&D, In Brief
Genzyme Plays Up Emerging Blood Cancer Business In R&D Review
Genzyme Plays Up Emerging Blood Cancer Business In R&D Review
Faster Pace For Duchenne MD Research
PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
PTC Advances Cystic Fibrosis Candidate On Encouraging Data
PTC Advances Cystic Fibrosis Candidate On Encouraging Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS069273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel